AMARILLO, Texas (KFDA) – Across the country, young people aged 12 to 17 have started receiving Pfizer and Moderna COVID-19 vaccines as part of clinical trials in adolescents.
Among the 3,000 enrolled in the one-year Moderna vaccine trial is Grade 7 student Wyatt Barnett.
At 12, Barnett barely managed to register.
He says the idea was first brought up by his parents and after some research and the green light from his pediatrician he thought to himself, “Well, if he ends up getting it, why not? not do it now? “
He was approved and assigned to the test group at the Lynn Institute in Oklahoma City. He and his family visited the institute last week when he received the first of two doses.
For this trial, there is a 66% chance that Barnett will receive the actual dose instead of the placebo.
“I hope I got the vaccine and that way I can just be immune for as long as they say,” Barnett said.
As part of the test, he checks his temperature and fills out an online questionnaire daily. So far no fever or other symptoms.
Barnett says he enjoys having this responsibility and just wants to get back to some form of normalcy.
“I was just ready to get it; I’m sick of having to stay home and getting sick and people dying and getting sick from it all. I want to see my grandparents again, you know that would be nice, ”Barnett said.
Not only does he miss his grandparents, but he’s ready to return to the field to play football and baseball without fear of being infected.
The trial will end in June of next year, but like the ongoing adult trials, it is expected to get emergency clearance sooner.
“The public should expect Moderna, as soon as they get enough data, probably within two months, to table an amendment to their EUA to try to extend that EUA up to 12 years,” he said. said Carlos Blanco, CEO and President. of Lynn Institute of Health Sciences.
He says they have no reason to believe it won’t work, but the main priority is to make sure the vaccine is as safe and effective for this age group as it is for adults.
Barnett expects to receive his second dose this spring and health experts believe data to be filed for authorization for this age group will be available in the fall.
If approved, they plan to open the clinical trial for people aged 2 to 11.
Copyright 2021 KFDA. All rights reserved.